Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is lymphotropic and has been associated with 3 distinct lymphoproliferative disorders: primary effusion lymphoma (PEL), multicentric Castleman disease (MCD), and MCD-associated plasmablastic lymphoma. [1] [2] [3] [4] [5] KSHV/HHV-8-associated lymphomas occur mostly in HIV-seropositive or other immunosuppressed patients, 6, 7 suggesting an association among immunosuppression, KSHV/HHV-8 infection, and lymphomagenesis. Posttransplant lymphoproliferative disorders (PTLDs) are a heterogeneous group of lymphoproliferative disorders that occur exclusively in iatrogenically immunosuppressed recipients following solid organ or bone marrow transplantation. 8 Clinically and pathologically, PTLDs represent a spectrum of diseases ranging from early Epstein-Barr virus (EBV)-driven polyclonal B-cell proliferations to morphologic and genetically or molecularly defined malignant lymphomas. 8 A clear relationship between KSHV/HHV-8 infection and the pathogenesis of PTLDs remains largely unknown. In the present study, we investigated the role of KSHV/HHV-8 in a large series of various PTLDs in 43 organ recipients, using immunohistochemical and molecular studies.
Materials and Methods

Case Selection
We retrieved 52 cases of PTLD based on the current World Health Organization (WHO) classification from the archives of the Department of Pathology and Laboratory Medicine, Upon completion of this activity you will be able to:
• list the 4 main types of posttransplant lymphoproliferative disorders (PTLDs) as classified by the World Health Organization and relate each to the likelihood of being associated with a monoclonal lymphocytic proliferation.
• describe the mechanism of interaction of Epstein-Barr virus (EBV) infection with the immunologic abnormalities in the transplant patient that leads to the clinical features of PTLD and the likelihood of detecting evidence of EBV in the early vs the late stages of PTLD.
• state the relative frequencies of PTLD in solid organ vs bone marrow transplantation patients.
• list the conditions that are known to be associated with Kaposi sarcoma-associated herpesvirus, ie, human herpesvirus 8.
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Histologic and Immunohistochemical Studies
All specimens were fixed in 10% neutral buffered formalin, and representative sections were embedded in paraffin, sectioned at 3-to 4-µm thickness, and stained with standard H&E or hematoxylin counterstain for immunohistochemical analysis. 9 Immunohistochemical staining of paraffin sections was performed using a heat-induced epitope retrieval technique and a universal secondary antibody kit that used a peroxidase-conjugated labeled dextran polymer (EnVision+ System, Peroxidase; DAKO, Carpinteria, CA). A commercially purchased primary antibody directed against the KSHV/ HHV-8 latent nuclear antigen 1 (LNA-1) protein was used (dilution 1:2,500; ABI, Columbia, MD). Diaminobenzidine was used as a chromogen. Normal rabbit and/or mouse serum was used as a negative control sample. Additional control samples omitted the primary antibody.
EBV In Situ Hybridization Analysis
EBV in situ hybridization was performed on paraffin sections with a 30-base-pair (bp) biotin-labeled probe (59-AGA CAC CGT CCT CAC CAC CCG GGA CTT (G/C/T)TA-39) specific for EBV early RNA-1 (EBER-1) according to standard protocols as previously described. 10 Besides a nonprobe hybridization control, a known EBV+ tissue control sample was run with each batch. We also ran a positive control sample by the use of a poly-d(T) probe (59-TTT TTT TTT TTT TTT TTT TTT TTT T-39) with each case and control to check viability of the RNA and a non-EBV negative control sample by using a non-EBV probe (59-AGA GTG CGT GGA CAC GTG CCG CCT GAA GTA-39) with each case and control to rule out possible contamination. The biotin label was detected by using streptavidin-alkaline phosphatase conjugate. The site of hybridization was visualized by the colorimetric reaction for the enzyme on the substrate, 5-bromo-4-chloro-3-indolyl phosphate, and the accompanying reduction of nitroblue tetrazolium. Unequivocal brown-black staining of the cell nuclei of interest was interpreted as positive.
Molecular Analysis for KSHV/HHV-8
DNA was extracted from paraffin-embedded tissues using the QIAamp DNA FFPE Tissue Kit (QIAGEN, Valencia, CA) according to the manufacturer's instructions. Briefly, 5-µm-thick sections were cut from each paraffin block, or, in cases in which unstained paraffin sections were the only material available, they were scraped off slides into a microcentrifuge tube. For bone marrow specimens, only formalin-fixed, paraffin-embedded trephine core biopsy specimens and/or marrow aspirate clots were used for DNA extraction. The tissue was then deparaffinized with xylene, washed twice with 100% ethanol, and digested with Proteinase K overnight, followed by applying cell lysis buffer to get a raw DNA solution and then followed by washing with 55% ethanol and 70% ethanol. Depending on the amount of tissue, DNA was eluted in pure water and stored at -20°C until the next step.
For detection of KSHV/HHV-8 viral sequences by polymerase chain reaction (PCR)-hybridization, the primers 59-AGC CGA AAG GAT TCC ACC ATT-39 and 59-ATC CGT GTT GTC TAC GTC CA-39 were designed specifically for the viral sequence. 9, 11, 12 PCR was performed in a 25-µL system: DNA (250 ng/µL), 4 µL; deionized-distilled water, 12.4 µL; 10× PCR buffer, 2.5 µL; deoxyribonucleotide triphosphate, 4 µL; forward and reverse primers, 1 µL; and Taq Gold DNA polymerase, 0.1 µL. The amplification was carried out for 45 cycles starting with denaturation at 94°C for 1 minute and then primer annealing at 58°C for 1 minute, followed by extension at 73°C for 1 minute. KSHV/ HHV-8 sequence-containing plasmid and/or genomic DNA samples from known KSHV/HHV-8+ patients (with PEL) were used as positive control samples. Genomic DNA of a known KSHV-patient and water were used as negative control samples. The amplified PCR products were then separated by electrophoresis on 1.5% agarose gel, stained with ethidium bromide, and transferred to an Amersham Hybond-N+ membrane (GE Healthcare, Pittsburgh, PA) in freshly diluted 0.4 sodium hydroxide for at least 2 hours. For maximizing hybridization capacity, the membrane was neutralized by washing with 2× saline sodium citrate (sodium chloride, 17.5 g; sodium citrate dihydrate, 8.8 g; distilled water, pH 7.0, 1 L) for 15 minutes twice and prehybridization with the PCR hybridization solution (20× SSPE buffer [sodium chloride, 175.3 g; sodium phosphate, dibasic, heptahydrate, 27.6 g; ethylenediamine tetraacetic acid, 7.4 g; distilled water, pH 7.4, 1 L], 25 mL; 10% nonfat dry milk, 5 mL; 20% sodium dodecyl sulfate, 2.5 mL; single-stranded DNA, 500 µL; and distilled water, 100 mL) for 30 minutes at 55°C.
Hybridization was performed in the PCR hybridization solution with a fluorescein-labeled KSHV probe, 59-GGA ACT TGA TCT ATA TAC CAC-39, at a 1:6,000 dilution at 55°C overnight. Signal detection was performed by using the chemiluminescent detection system (DAKO, Glostrup, Denmark) according to the manufacturer's instructions. Briefly, unbound probe was removed by 3 washes in Stringent Buffer (DAKO) at 55°C. After blocking by Blocking Solution (DAKO) for 30 minutes at room temperature, anti-fluorescein alkaline phosphatase antibody was applied at a 1:32,000 dilution for 30 minutes, followed by 3 gentle washes in tris(hydroxymethyl)aminomethane-buffered saline-polysorbate 20-sodium azide at room temperature.
Finally, the membrane was incubated in substrate for 60 minutes at 0.05 mL/cm 2 in darkness, and signals were developed by film exposure. The β-globin housekeeping gene was used as an internal control for ensuring DNA quality and was used for every specimen. The size of the amplified products of KSHV/HHV-8 was about 234 bp, while the β-globin product was about 175 bp.
Results
The major clinical features and special study results are summarized in zTable 1z.
Clinical Features and PTLD Categories
The 52 cases of PTLD were obtained from 43 
KSHV/HHV-8 LNA-1 Immunohistochemical Findings
Immunohistochemical staining for the KSHV/HHV-8 LNA-1 protein was performed in all except 1 of the PTLD cases, and no KSHV/HHV-8 LNA-1 protein was detected in any of the cases tested (Table 1) .
EBER In Situ Hybridization and Molecular Findings for the KSHV/HHV-8 Genome
Of the 50 cases tested, 92% (46/50) were positive for EBV infection as demonstrated by EBER in situ hybridization, with staining noted in the nuclei of the proliferating lymphoid cells or plasma cells zImage 2z. All specimens from the 46 PTLD cases with available extracted genomic DNA showed complete absence of KSHV/HHV-8 DNA by PCRhybridization analysis zImage 3z.
Discussion
The detection of herpesvirus-like DNA in tumor tissue of patients with Kaposi sarcoma by Chang et al 11 and subsequently confirmed by others 12 led to the discovery of a new human herpesvirus known as KSHV or HHV-8, which belongs to the subfamily of γ-herpesviruses related to the EBV and represents the first member of a human γ 2 -herpesvirus, genus Rhadinovirus. 13, 14 Seroepidemiologic data have also confirmed a strong correlation between Kaposi sarcoma and KSHV/HHV-8 infection. [15] [16] [17] KSHV/HHV-8 is present in almost all variants of Kaposi sarcoma, and its DNA can be detected in 95% to 100% of cases of Kaposi sarcoma by using a nested PCR; the detection of the virus is useful as a diagnostic test for the disease. 18 It has also been demonstrated that transplant recipients with KSHV/HHV-8 infection have a significantly increased risk of developing Kaposi sarcoma, similar to HIV-infected patients. 19 Besides Kaposi sarcoma, this virus has also been shown to be associated with 3 distinct lymphoproliferative disorders: PEL, MCD, and MCD-associated plasmablastic lymphoma. 1-5 KSHV/HHV-8 has been localized to the malignant cells in Kaposi sarcoma and PEL. [20] [21] [22] [23] [24] In vitro studies have shown at least some evidence of transforming capacity by KSHV/HHV-8. [25] [26] [27] Although it is controversial, the presence of KSHV/ HHV-8 DNA in various other diseases and lesions has been reported by some investigators, including cultured bone marrow stromal dendritic cells 28 and bone marrow biopsy specimens from patients with multiple myeloma, 29 HIV-associated plasmacytosis, and a proportion of patients with monoclonal gammopathy of unknown significance. 28 In these groups of diseases and lesions, KSHV/HHV-8 has been demonstrated to localize in the bone marrow stromal dendritic cells rather than in the neoplastic plasma cells. 28, 29 It has been hypothesized that KSHV/HHV-8 indirectly promotes growth of myeloma cells via secretion of the viral cytokine homologue, viral interleukin-6. 28 Nevertheless, subsequent studies have clearly demonstrated that KSHV/HHV-8 is not involved in the pathogenesis of multiple myeloma. [30] [31] [32] In addition, the detection of KSHV/HHV-8 DNA in epithelial skin tumors following solid organ transplantation, 33 zImage 2z Epstein-Barr virus (EBV) genomes were detected in many nuclei of the lymphoplasmacytic cells by EBV-encoded RNA-1 in situ hybridization (×100).
zImage 3z Molecular polymerase chain reaction-hybridization analysis failed to demonstrate the presence of Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 DNA in various tested cases of posttransplant lymphoproliferative disorder (lanes 1-16) (+, positive control sample; -, negative control sample).
sarcoidosis, 34 angiolymphoid hyperplasia, 35 and pemphigus vulgaris/foliaceus 36 have also been described. However, most of these findings have not been confirmed by other investigators, so that the role of KSHV/HHV-8 in these lesions remains highly controversial and uncertain. 18 Transplant recipients have a 50-to 100-fold increased prevalence of non-Hodgkin lymphoma that is directly related to the degree of immunosuppression, with an overall incidence of 1% to 5% in solid organ recipients and 1% in marrow recipients. The clinically and histologically heterogeneous group of monoclonal or reactive polyclonal lymphoproliferative lesions that occur in immunosuppressed recipients following solid organ or bone marrow transplantation are collectively referred to as PTLDs. 8, 37, 38 Most PTLDs are associated with EBV infection in a setting of decreased host T-cell immune surveillance, particularly cytotoxic T lymphocytes, leading to an unchecked EBV-infected B-lymphocyte proliferation and eventual PTLD. 39 This model agrees with the observation that EBV+ PTLD cases tend to occur earlier (median interval, 6-10 months) than EBV-cases (4-5 years), which are also more likely to be of the monomorphic type.
The current WHO classification includes 4 categories of PTLD: (1) early lesions (reactive plasmacytic hyperplasia and infectious mononucleosis-like PTLD), (2) polymorphic PTLD, (3) monomorphic PTLD (including B-and T-cell neoplasms), and (4) HL and HL-like PTLD; all categories are monoclonal except the early lesions. 8 Although most PTLDs are EBV+ and seem to represent EBV-induced proliferations of monoclonal (or less often polyclonal) B, T, or plasma cells, a subset of PTLDs is EBV-.
Because KSHV/HHV-8 has been clearly demonstrated in association with the development of some hematolymphoid and nonhematolymphoid neoplasms [1] [2] [3] [4] [5] and the KSHV/HHV-8-associated lymphomas occur mostly in HIV-seropositive or other immunosuppressed patients, KSHV/HHV-8 infection has been suggested to have an important role in lymphomagenesis in immunosuppressed patients. 6, 7 In addition, it has been demonstrated that transplant recipients with KSHV/ HHV-8 infection have a significantly increased risk of developing Kaposi sarcoma, similar to HIV-infected patients. 19, 33, 40 As mentioned, the development of PTLDs substantially simulates the immunodeficiency of HIV infection except that the immunosuppression is iatrogenic and the patients are solid organ and bone marrow transplant recipients, raising a possible role of KSHV/HHV-8 in the pathogenesis of PTLDs.
In this study, we investigated whether there is an association between KSHV/HHV-8 and PTLDs by detection of KSHV/HHV-8 LNA-1 protein and DNA using immunohistochemical analysis and KSHV/HHV-8-specific PCR analysis. Our series included 52 cases of various PTLDs from 43 organ transplant recipients. However, none of the 51 tested cases demonstrated expression of KSHV/HHV-8 LNA-1 protein by immunohistochemical analysis, and, furthermore, all 46 PTLD cases with available extracted genomic DNA showed complete absence of the KSHV/HHV-8 genome by specific PCR-hybridization analysis.
The seroprevalence of KSHV/HHV-8 varies greatly worldwide, with 1% to 10% of people infected in developed countries and up to 80% of people infected in some areas of sub-Saharan and equatorial Africa. 41 However, only a few cases of KSHV/HHV-8+ benign lymphoid tissues were reported previously, 11, 35, 42 including florid germinal center hyperplasia (giant follicles), regression of germinal centers (follicular involution), increased vascularity, and "monocytoid B-cell" hyperplasia. 35 We, however, did not detect any positivity for KSHV/HHV-8 in our series of 52 PTLD cases. Whether the differences were due to the different specimens used (PTLD vs reactive lymphadenopathy) or the different geographic distribution of KSHV (4 of the HHV-8+ benign lymphadenopathy cases reported previously were from Italy, where there exists a higher occurrence of Kaposi sarcoma with a possible higher KSHV infection rate) 43 is not known. Further study with cases of benign lymphadenopathy in a large US population would be worthwhile to address this issue.
With regard to sensitivity of the test, PCR amplification and detection of the KSHV/HHV-8 viral genome has been recommended as a quick indicator. 11 The sensitivity of the primer set we used in the present study was reported previously by Pan et al 30 and was in the range of 0.1 to 0.01 ng. Furthermore, the specificity of this approach has been improved by using internal fluorescent-labeled oligonucleotide probes that target the PCR product in hybridization assays to confirm the viral origin of the DNA template. 35 Despite the parallels between the development of lymphoma or PTLD in patients who are immunosuppressed due to HIV infection and those who are iatrogenically immunosuppressed following transplantation, our study failed to find any association between KSHV/HHV-8 and PTLD in a wide variety of types of PTLD, as assessed by immunohistochemical analysis and PCR-hybridization. Thus, our data indicate that KSHV/HHV-8 is not associated with lymphoproliferative disorders in the iatrogenically immunosuppressed post-organ transplantation setting. The findings also suggest that the mechanism of lymphomagenesis in KSHV/HHV-8-infected HIV+ patients is in some way fundamentally different from that of EBV-associated PTLD in the posttransplant setting. The basis of this difference is worthy of further investigation and may provide important clues to improved management.
